Polyvidone demand rising in U.S. pharma
Market analysis shows rising U.S. demand for polyvidone (PVP)—a pharmaceutical excipient used to improve stability and manufacturing efficiency—which is driving supply‑chain interest across drugmakers reported. That supply pressure can indirectly impact device makers who rely on integrated pharma/device combinations or contract manufacturers.
Market forecasts estimate PVP supply at 101.85 kilotons in 2026 with an 8.17% CAGR projected through 2031. mordorintelligence.com Industry analyses name Ashland, BASF, Nippon Shokubai and Kuraray as dominant suppliers, and BASF publishes cGMP PVP production sites across Asia, the U.S. and Europe. mordorintelligence.com Technical literature and vendor application notes show PVP deployed as a hydrophilic, lubricious coating on catheters, guidewires and delivery systems. hydromer.com The FDA’s guidance on lubricious coatings for intravascular devices details the labeling and testing expectations for polymer-based coatings. fda.gov Contract manufacturers report increased need to integrate drug–device GMPs and expanded design‑verification workflows as combination‑product volumes rise, according to industry guidance and CMO primers. mastercontrol.com The FDA’s device‑shortage tools and the 506J notification framework require manufacturers to report interruptions that could result from excipient‑driven disruptions to prefilled syringes or coated‑device supply chains. fda.gov
